TEVA - Teva Pharma Industries Ltd ADR

Exchange: USA Stocks • Country: Israel • Currency: USD • Type: Common Stock • ISIN: US8816242098

Generic Medicines, Specialty Medicines, Biopharmaceuticals

Teva Pharmaceutical Industries Limited is a global leader in the development, manufacturing, and distribution of a wide range of pharmaceutical products, including generic medicines, specialty medicines, and biopharmaceuticals. The company operates in over 60 countries, with a strong presence in North America, Europe, Israel, and other international markets.

Teva's generic medicine portfolio is extensive, offering a variety of dosage forms such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. The company specializes in producing high-quality, affordable generic versions of branded medicines, including sterile products, hormones, high-potency drugs, and cytotoxic substances. Additionally, Teva offers generic products with medical devices and combination products, catering to diverse patient needs.

The company has a strong focus on three key therapeutic areas: central nervous system (CNS), respiratory, and oncology. In CNS, Teva offers treatments for conditions such as multiple sclerosis, migraine, and neurodegenerative disorders. In respiratory, the company provides inhalation products for asthma and chronic obstructive pulmonary disease (COPD). In oncology, Teva offers injectable treatments for various types of cancer, including chronic lymphocytic leukemia and non-Hodgkin's lymphoma.

Teva also provides active pharmaceutical ingredients (APIs) and contract manufacturing services to other pharmaceutical companies. Its out-licensing platform offers a portfolio of products to partners, enabling them to expand their offerings. The company has collaboration agreements with several partners, including MedinCell, Sanofi, Alvotech, and Biolojic Design Ltd., to develop and commercialize new products.

In addition to its prescription medicines, Teva offers a range of over-the-counter (OTC) products under various brand names, including SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA. These products cater to everyday healthcare needs, such as skin care, pain relief, and respiratory health.

Founded in 1901, Teva Pharmaceutical Industries Limited is headquartered in Tel Aviv, Israel, and has a rich history of innovation and growth. Today, the company is a leading global pharmaceutical player, committed to improving healthcare outcomes and making quality medicines accessible to patients around the world.

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for TEVA - Teva Pharma Industries Ltd ADR

Overall Trend and Yearly Seasonality

Drawdown / Underwater Chart for TEVA - Teva Pharma Industries Ltd ADR

TEVA Stock Overview

Market Cap in USD 19,051m
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
GiC SubIndustry Pharmaceuticals
TER 0.00%
IPO / Inception 1990-03-26

TEVA Stock Ratings

Growth 5y 43.1
Fundamental -1.12
Dividend 11.5
Rel. Performance vs Sector 2.75
Analysts 3.92/5
Fair Price Momentum 18.43 USD
Fair Price DCF 27.30 USD

TEVA Dividends

Dividend Yield 12m 0.00%
Yield on Cost 5y 0.00%
Dividends CAGR 5y 0.00%
Payout Consistency 73.0%

TEVA Growth Ratios

Growth 12m 99.77%
Growth Correlation 12m 75%
Growth Correlation 3m 30%
CAGR 5y 16.79%
CAGR/Mean DD 5y 0.70
Sharpe Ratio 12m 2.63
Alpha vs SP500 12m 75.67
Beta vs SP500 5y weekly 1.21
ValueRay RSI 39.24
Volatility GJR Garch 1y 38.27%
Price / SMA 50 2.15%
Price / SMA 200 32.15%
Current Volume 9088.5k
Average Volume 20d 9052k

External Links for TEVA Stock

News
Wall Street JournalBenzingaYahoo Finance
Tweets
XStocktwits
Fund Manager Positions
DataromaStockcircle
What is the price of TEVA stocks?
As of July 27, 2024, the stock is trading at USD 17.10 with a total of 9,088,470 shares traded.
Over the past week, the price has changed by +1.73%, over one month by +5.23%, over three months by +23.82% and over the past year by +103.57%.
What are the forecast for TEVA stock price target?
According to ValueRays Forecast Model, TEVA Teva Pharma Industries Ltd ADR will be worth about 19.9 in July 2025. The stock is currently trading at 17.10. This means that the stock has a potential upside of +16.61%.
Issuer Forecast Upside
Wallstreet Target Price 19 11.1
Analysts Target Price 10.6 -38.2
ValueRay Target Price 19.9 16.6